文献速递食管与纵隔外科

新辅助化疗免疫治疗后淋巴结清扫范围的多中心真实世界研究

Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-12-08

该多中心回顾性队列纳入724例局部晚期食管鳞癌患者,在新辅助化疗免疫治疗后行食管切除术,以19枚淋巴结为界分组。清扫>19枚者2年总生存率显著优于≤19枚者(83.6% vs 77.8%),总体并发症无显著差异但肺炎等特定并发症增加,支持系统性淋巴结清扫。

要点

  • 清扫>19枚淋巴结与更好的2年OS相关(83.6% vs 77.8%)。
  • 清扫>19枚不增加总体并发症率,但肺炎、吻合口漏和喉返神经麻痹更多。
  • 2年DFS、局部区域复发和远处转移在两组间无显著差异。

核心结论

  • 新辅助化疗免疫治疗后清扫>19枚淋巴结与改善的2年OS相关,且不增加总体并发症率。
  • 结果支持在现代食管鳞癌管理中实施系统性淋巴结清扫。

研究设计与样本

  • 多中心回顾性队列研究,纳入8个高容量中心的724例局部晚期食管鳞癌患者。
  • 患者于2019年1月至2023年3月接受新辅助化疗免疫治疗后食管切除术。
  • 采用限制性立方样条建模淋巴结清扫总数,以最大选择秩统计确定19枚为最佳阈值。
  • 按清扫淋巴结数分为≤19枚组和>19枚组,主要终点为2年OS。

主要发现

  • 中位年龄61.0岁(四分位距56.0-67.0岁),男性占79.8%。
  • 清扫>19枚组2年OS为83.6%,≤19枚组为77.8%(HR 1.56,95%CI 1.13-2.15,P<.001)。
  • 2年DFS无显著差异(76.2% vs 73.5%;HR 1.09,95%CI 0.80-1.50,P=.187)。
  • 局部区域复发率(13.3% vs 18.0%,P=.083)和远处转移率(13.5% vs 13.8%,P=.922)相似。
  • 总体并发症率无显著差异(56.5% vs 48.7%,P=.073),但清扫>19枚组肺炎(P<.001)、吻合口漏(P=.012)和喉返神经麻痹(P=.018)发生率更高。

关键数值与推荐

  • 以清扫19枚淋巴结为最佳OS阈值(最大选择秩统计确定)。
  • 清扫>19枚组2年OS 83.6%,≤19枚组77.8%(HR 1.56,95%CI 1.13-2.15,P<.001)。
  • 总体并发症率56.5% vs 48.7%(P=.073),肺炎、吻合口漏、喉返神经麻痹差异有统计学意义。

临床怎么用

  • 在新辅助化疗免疫治疗后的食管鳞癌手术中,可考虑系统性清扫超过19枚淋巴结以改善2年OS。
  • 需权衡特定并发症(肺炎、吻合口漏、喉返神经麻痹)风险,加强术后管理。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素。
  • 最佳阈值19枚基于统计方法确定,需外部验证。
  • 未报告无病生存以外的长期随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal extent of lymph node dissection (LND) following neoadjuvant chemoimmunotherapy (NCIT) for esophageal squamous cell carcinoma (ESCC) remains unclear, with concerns regarding postoperative immunosuppression and survival benefit. METHODS: A multicenter retrospective cohort study was conducted across 8 high-volume centers, including 724 patients with locally advanced ESCC who underwent NCIT followed by esophagectomy between January 2019 and March 2023. The number of total LNDs was modeled as a continuous variable using restricted cubic splines, and the optimal LND threshold for overall survival (OS) was determined using maximally selected rank statistics ("maxstat" package in R), identifying 19 nodes as the cut-off. Patients were grouped into LND ≤19 and LND >19. The primary endpoint was 2-year OS; secondary endpoints included 2-year disease-free survival (DFS), postoperative complications, recurrence, and distant metastasis. Multivariable Cox regression adjusted for clinicopathologic variables. RESULTS: The median patient age was 61.0 years (interquartile range, 56.0-67.0 years); 79.8% were male. Patients with LND >19 had significantly better 2-year OS compared with those with LND ≤19 (83.6% vs 77.8%; hazard ratio [HR], 1.56, 95% confidence interval [CI], 1.13-2.15; P < .001). There was no significant difference in 2-year DFS (76.2% vs 73.5%; HR, 1.09; 95% CI, 0.80-1.50; P = .187). Rates of locoregional recurrence (13.3% vs 18.0%; P = .083) and distant metastasis (13.5% vs 13.8%; P = .922) were similar. Overall complication rates did not differ significantly (56.5% vs 48.7%; P = .073), although higher incidences of pneumonia (P < .001), anastomotic leak (P = .012), and recurrent laryngeal nerve palsy (P = .018) were observed in the LND >19 group. CONCLUSIONS: Dissection of >19 lymph nodes after NCIT is associated with improved 2-year OS without increasing overall morbidity, supporting systematic LND in modern ESCC management.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chen C, Lv H, Zhao J, et al. Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study. J Thorac Cardiovasc Surg. 2025. PMID: 41371580. doi:10.1016/j.jtcvs.2025.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。